Ambrx Biopharma

Ambrx is now officially part of . With our world-class team and novel ADC product
candidates, we have exciting opportunities ahead to advance and deliver novel targeted therapies for
patients with cancer. Read here:

Johnson & Johnson Completes Acquisition of Ambrx Acquisition strengthens Johnson Johnson’s commitment to innovation in prostate cancer and deepens pipeline of next-generation antibody drug conjugates and targeted oncologic therapeutics Johnson Johnson (NYSE: JNJ) announced today it has successfully completed the acquisition of Ambrx Biopharma, I...

ARX517, Ambrx's PSMA–directed antibody-drug conjugate (ADC), demonstrated promising safety and efficacy in the APEX-01 trial in patients with metastatic castration-resistant (mCRPC). No serious adverse events or DLTs were observed in the Phase 1/2 clinical trial. Read more in Targeted Oncology.

ARX517 Shows Promising Safety and Efficacy in mCRPC No serious adverse events or dose-limiting toxicities were observed in the phase 1/2 trial of the antibody drug conjugate ARX517.

Updated results from the Phase 1/2 APEX-01 clinical trial of ARX517 demonstrate continued safety and anti-tumor activity in patients with metastatic castration-resistant prostate cancer (mCRPC). Read more in Urology Times. https://bit.ly/484KUj0

ARX517 demonstrates continued safety and efficacy in mCRPC The investigators observed no dose limiting toxicities or serious adverse events among all patients who received an ARX517 dose of 3.4 mg/kg, the highest dose tested in the trial.

John Shen, MD, spoke with OncLive about the unique features associated with the use of Ambrx's PSMA–directed antibody-drug conjugate (ADC) ARX517 in patients with metastatic castration-resistant prostate cancer (mCRPC) and highlighted data presented at from the ongoing Phase 1/2 APEX-01 trial of ARX517. For more: https://bit.ly/473VzKK

Dr Shen on the Tolerability and Efficacy of ARX517 in mCRPC John Shen, MD, discusses unique features associated with the use of the prostate-specific membrane antigen–directed antibody-drug conjugate ARX517 in patients with metastatic castration-resistant prostate cancer and highlights early efficacy and safety findings with this agent.

This Sunday, November 5th, Ambrx will walk to raise awareness for at the 2023 San Diego Susan G. Komen walk. Learn about the event and join our team here: https://bit.ly/3u6bUzX

Thank you to all who attended Ambrx's KOL event discussing the ARX517 data presented at the 2023 European Society for Medical Oncology (ESMO) Congress meeting. A webcast replay of the event is available here: https://bit.ly/475J7dj

Ambrx's CEO Dan O'Connor and Chief Scientific Officer Shawn Zhang, Ph.D. spoke with BioTechTV's Brad Loncar about our two (ADC) programs, ARX788 Anti-HER2 ADC and ARX517 Anti-PSMA ADC, both of which are potential treatments for cancer indications with high unmet medical need. Listen to the interview here:

Ambrx's CEO & CSO discuss the ADC space and recent #ESMO23 data Dan O'Connor and Shawn Zhang describe Ambrx's HER2 and PSMA targeting antibody-drug conjugate programs.

In newly published data from Ambrx's ongoing Phase 1/2 APEX-01 trial of ARX517 in mCRPC presented at , ARX517 was shown to display preliminary efficacy and a strong safety profile in patients with mCRPC. Read the OncLive article here: https://bit.ly/46NXjYy

ARX517 Demonstrates Early Efficacy With Favorable Safety in Heavily Pretreated mCRPC ARX517 displayed preliminary efficacy and a strong safety profile in patients with metastatic castration-resistant prostate cancer, according to findings from the phase 1/2 APEX-01 study.

Fierce Biotech highlighted the recent data presented at from the ongoing Phase 1/2 APEX-01 trial of the antibody-drug conjugate ARX517 in mCRPC showing anti-cancer activity and few adverse events—none serious. Read more: https://bit.ly/495pyDP

ESMO: Ambrx's 'reset' arrives at the last line of prostate cancer, offering the kind of safety rarely seen MADRID—When patients reached Ambrx Biopharma’s phase 1/2 clinical trial for prostate cancer, they were nearing the end of their treatment journey. | When patients reached Ambrx Biopharma’s phase 1/2 clinical trial for prostate cancer, they were nearing the end of their treatment journey. CEO D...

Dr. Oliver Sartor, a medical oncologist and translational researcher with 33 years of professional experience and a special focus on , comments on the newly published data from the ongoing Phase 1/2 APEX-01 trial of ARX517 in mCRPC presented at . For more: https://bit.ly/3tM8e6v

Dr. John Shen, a medical oncologist at UCLA and an investigator on APEX-01, comments on the updated data from the on-going Phase 1/2 APEX-01 trial of ARX517 in metastatic castration-resistant (mCRPC) presented at . For details: https://bit.ly/3tM8e6v

ICYMI - Ambrx hosted a KOL event discussing the ARX517 data presented at the 2023 European Society for Medical Oncology (ESMO) Congress meeting showcasing presentations from pharmacokinetics and prostate cancer experts. View the webcast replay here: https://bit.ly/475J7dj

Ambrx today announced that in biomarker unselected patients ARX517 monotherapy demonstrated a strong antibody-drug conjugate (ADC) safety profile at all doses tested with promising early efficacy signals that included PSA50 declines, ctDNA reductions, and RECIST v1.1 tumor response. The ESMO clinical posters present updated safety, efficacy and PK data from Ambrx’s on-going trial, APEX-01 (NCT04662580). Posters were made available as part of the 2023 European Society for Medical Oncology (ESMO) Congress 2023 meeting, taking place in Madrid, Spain, October 20-24, 2023. For details: https://bit.ly/3tM8e6v

Ambrx's posters and ARX517 slide deck to be presented during the 2023 ESMO - European Society for Medical Oncology Congress meeting are now available. To view them, please visit: https://bit.ly/490bP0X

Reminder: Ambrx will host a KOL event discussing ARX517 data presented at tomorrow, October 22nd at 8 pm CEST/2 pm ET. Register for both the in-person event and virtual webcast here: https://bit.ly/467jUin

Are you attending ESMO Congress 2023? Join us on Sunday, October 22nd at 8 pm CEST/2 pm ET for a KOL event discussing ARX517 data presented at . For those who are unable to attend in-person, a virtual webcast of the event will be available. Register here: https://bit.ly/467jUin

In an interview with , our CEO Dan O'Connor gave an update on Ambrx's two ADC programs, ARX788 Anti-HER2 ADC and ARX517 Anti-PSMA ADC, both of which are potential treatments for cancer indications with high unmet medical need. Read more: https://bit.ly/3M9bM90

Ambrx today announced that two abstracts detailing safety and efficacy data from the ongoing Phase 1/2 trial, APEX-01 (NCT04662580), evaluating ARX517 for metastatic castration-resistant prostate cancer (mCRPC) were made available as part of the 2023 European Society of Medical Oncology (ESMO) Congress meeting, taking place in Madrid, Spain, October 20-24, 2023. For details: https://bit.ly/3rS3I5S

Attending the 14th Annual Conference next week? Shawn Zhang, Ph.D., Ambrx Chief Scientific Officer, will present on Monday, October 16th and Ying Buechler, Ph.D., Ambrx Chief Technology Officer, will participate in a panel discussion on Tuesday, October 17th. Learn more about the event: worldadc-usa.com

Ambrx is proud to partner with the 14th Annual Conference! We look forward to joining other experts in San Diego, CA on October 16-19, 2023. Check out the full agenda here: worldadc-usa.com

Thank you to all who attended Ambrx CEO Dan O'Connor's fireside chat at ! We look forward to presenting preliminary safety, efficacy & PK data from APEX-01, a 1st-in-human study evaluating ARX517 in patients, at next month.